SCHEMBL30737878

SCHEMBL30737878

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(CCCN(C)C)C(C)=O)cc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 1/20 0.37
CASP1 P29466 1/20 0.36
CHEK1 O14757 1/20 0.35
DAPK3 O43293 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
RET P07949 1/20 0.35
MET P08581 1/20 0.35
PDGFRB P09619 1/20 0.35
PIM1 P11309 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
LTK P29376 1/20 0.35
KDR P35968 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
GSK3A P49840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436187 1.00 SENP1 (0.37) SENP1CASP1CHEK1DAPK3PRKD3
SCHEMBL436186 1.00 SENP1 (0.37) SENP1CASP1CHEK1DAPK3PRKD3
SCHEMBL30737799 0.95 SENP1 (0.38) SENP1CASP1CHEK1DAPK3PRKD3
SCHEMBL2571796 0.95 SENP1 (0.38) SENP1CASP1CHEK1DAPK3PRKD3
SCHEMBL2571801 0.95 SENP1 (0.38) SENP1CASP1CHEK1DAPK3PRKD3
SCHEMBL31093978 0.93 RXFP1 (0.42) SENP1KMT2AMEN1TP53THRB
SCHEMBL2571237 0.93 RXFP1 (0.42) SENP1KMT2AMEN1TP53THRB
SCHEMBL2571239 0.93 RXFP1 (0.42) SENP1KMT2AMEN1TP53THRB
SCHEMBL3719902 0.93 RXFP1 (0.42) SENP1KMT2AMEN1TP53THRB
SCHEMBL26928300 0.93 BACE1 (0.36) CHEK1DAPK3PRKD3MAP4K4PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO claimed
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO disclosed